See the raw experimental evidence behind an author's publications and reproducibility signals.
Press Enter ↵ to solve
Fuel Your Discoveries
"The finding of the double helix thus brought us not only joy but great relief. It was unbelievably interesting and immediately allowed us to make a serious proposal for the mechanism of gene duplication."
- James Watson
Quick Explanation
Copied
Jalalifar Saba — scientific strength (evidence-based)
Based on the specific, citable record of publications provided (mostly review-type work spanning microbiota/gut–brain signaling, bacterial co-infections, microRNA/exosomal regulation, and antimicrobial resistance), the scientific profile looks strongest for synthesis/critical overview rather than primary mechanism discovery.
However, the provided evidence is insufficient to judge experimental rigor (methods, sample sizes, controls, reproducibility) for any specific claim because abstracts/full texts were not provided.
Long Explanation
BGPT Author Review: Jalalifar Saba
Science-focused critique from the provided OpenAlex-derived publication metadata (titles/DOIs/citation counts by year).
Date: April 27, 2026 | Epistemic stance: skeptical; claims only where the publication metadata/titles/DOIs support them.
1) Publication-signal map (from the provided record)
A) Research area clustering (titles/venues/DOIs)
The provided top works indicate a recurring focus on:
Microbiota / metabolites / gut–brain axis (e.g., “Role of microbiota-derived short-chain fatty acids in nervous system disorders”).
Infectious disease + bacterial co-infections (e.g., “Bacterial co-infections with SARS-CoV-2”).
MicroRNA / exosomal regulation in immunity/autoimmunity (e.g., “exosomal microRNA in autoimmune diseases”).
Antimicrobial resistance / bacterial genomics (integrons, resistance genes, serotypes) (e.g., integrons in P. aeruginosa; resistance in GBS).
B) Output type (review-heavy signals vs. original data signals)
In the provided top works list, many entries are explicitly labeled as review (e.g., gut SCFA review; SARS-CoV-2 co-infection review; exosomal microRNA review; OMVs review; probiotic review).
)
The record also includes at least some original research (e.g., integrons in P. aeruginosa; GBS resistance genetics/serotypes).
).
2) Citation dynamics (by year; from the provided record)
The following plots use the provided OpenAlex counts-by-year summary (works_count, cited_by_count, OA works_count). This is not a complete bibliometric analysis; it is a snapshot.
Critical note: cited-by counts are influenced by review-type articles (often garner broader citation), publication timing, and field-specific citation behavior; without article-level breakdown and full texts, we cannot infer causality.
3) Top work signals (title/DOI-level citable anchors)
The plot below uses the provided list of “top works” (title, year, type, cited_by_count, DOI). It does not guarantee these are the most influential works globally—only the most cited within the provided subset.
Interpretation caution: citation count is not equivalent to correctness or methodological quality. High citation can reflect topical relevance, review nature, and network effects.
4) Scientific strength: what we can and cannot conclude
What is supported by the provided record (DOI/title-level):
The publication portfolio includes multiple review-type works in microbiology/immunology-adjacent topics (gut metabolites/SCFAs, microRNA/exosomal signaling, outer membrane vesicles).
At least some works are original microbiology/genetics studies involving antimicrobial susceptibility/resistance mechanisms (integrons in P. aeruginosa) and bacterial population structure/resistance gene epidemiology (GBS).
The portfolio includes multi-host/pathogen interface themes (host immunity, gut-brain axis, autoimmune contexts), which often require careful bias handling when translating from mechanistic/animal findings to human relevance.
What cannot be judged from the provided evidence (major blind spot):
Experimental rigor in originals: sample sizes, assay QC, blinding/randomization (if any), statistical methods, and reproducibility checks are not available in the provided snippet. Example original titles exist, but their methods/results are not shown.
Review methodology quality: for reviews, the gold standard depends on search strategy, inclusion/exclusion criteria, and bias assessment (e.g., PRISMA-like rigor). Those details are not present here.
Potential overreach risk: many topics (microbiota → neuro/immune outcomes; exosomes/microRNA as therapeutic/diagnostic) have historically carried translational overreach risk when evidence is dominated by correlational or preclinical studies. The record confirms topic scope but not the correctness of specific claims.
Counterpoints / skeptical checks you should perform next (to fully validate scientific strength)
For each review: check whether the paper performed a systematic search, whether it distinguished mechanistic vs. clinical evidence, and whether it acknowledged uncertainty/heterogeneity.
For each original study: verify antibiotic susceptibility testing standards, integron detection methodology, genotyping approach, and whether appropriate statistical comparisons were made.
Translation barriers: confirm whether conclusions are limited by model systems (in vitro/in vivo) and whether human evidence is directly supported.
5) Direct citable “anchor reading list” (for the user)
Below are the key provided DOIs that define the author’s main thematic footprint. If you share PDFs/full text, BGPT can evaluate rigor line-by-line.
None (this query requests an author scientific review, not bioinformatics on sequence/structures or datasets).
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
That exosomal microRNA roles in autoimmunity are broadly established by clinical evidence alone—more likely the evidence is dominated by preclinical/correlational assays unless reviews show systematic clinical trial inclusion and strong confounder controls.
That probiotics universally mitigate COVID-19 outcomes—likely depends on strain, dosing, and endpoint definitions; without systematic inclusion criteria and stratification, conclusions can be overgeneralized.
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Quick Explanation
Long Explanation
Analysis Wizard
Hypothesis Graveyard
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight